Kronos Bio believes the most promising path forward for bringing a transformational therapy to patients for the treatment of AML is to focus the company’s SYK inhibitor program on lanraplenib, initially in the relapsed/refractory setting where the need is particularly acute.

In this assessment, the company projected significant delays due to several factors, including the operational challenges the company faced in enrolling a genetically defined subset of patients in a front-line setting, the residual and ongoing impacts of the COVID-19 pandemic, and the inability to activate planned clinical trial sites in Russia and Ukraine. Kronos Bio decided to end the trial after its recent review of enrollment data. The trial is not being discontinued due to adverse events or lack of efficacy signals. Patients already enrolled in the trial may complete their course of treatment. The company is discontinuing the Phase 3 trial of its SYK inhibitor, entospletinib, for the treatment of newly diagnosed patients with NPM1-mutated acute myeloid leukemia (AML) and plans to close the trial to further enrollment. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced the prioritization of its clinical portfolio to focus on the development of its next generation SYK inhibitor, lanraplenib, and its CDK9 inhibitor, KB-0742. 08, 2022 (GLOBE NEWSWIRE) - Kronos Bio, Inc. 30, 2022, Kronos Bio extends expected cash runway from Q4 2024 into Q2 2025Ĭonference call and webcast scheduled for today at 4:30 p.m.

With $270.3 million in cash, cash equivalents and investments as of Sept. Company on track to provide KB-0742 update from ongoing Phase 1/2 clinical trial in Q4

Solid edge v19 trial version